Tech Company Financing Transactions
Summit Therapeutics Funding Round
Summit Therapeutics, operating out of Miami, received $200 million from private investors.
Transaction Overview
Company Name
Announced On
6/3/2024
Transaction Type
Venture Equity
Amount
$200,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to advance the clinical development of ivonescimab, and for working capital and general corporate purposes.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
601 Brickell Key Drive 1000
Miami, FL 33131
USA
Miami, FL 33131
USA
Phone
Website
Email Address
Overview
Our mission is to make a significant difference for patients with high unmet medical needs, focusing on oncology. Our lead pipeline product candidate is a novel, bispecific antibody targeting both PD-1 and VEGF, ivonescimab. Summit has enacted the path to helping patients while creating opportunities for durable growth as a company by initiating two Phase III trials with the novel drug, ivonescimab.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bob Duggan
Chief Financial Officer
Bhaskar Anand
Chief Marketing Officer
Shelley Spray
Chief Medical Officer
Allen Yang
Chief Operating Officer
Manmeet Soni
President
Maky Zanganeh
Vice President
Noam Frey
VP - Bus. Development
Dave Gancarz
VP - Human Resources
Abby Murphy
VP - R & D
Betty Chang
VP - Regulatory Affairs
Urte Gayko
Browse more venture capital transactions:
Prev: 6/2/2024: CinRx Pharma venture capital transaction
Next: 6/3/2024: SiFi - Simplified Financial Solutions Company venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here come from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs